Randomized Trial of Preoperative Chemotherapy for Squamous Cell Cancer of the Esophagus

摘要: Of 77 patients with potentially resectable squamous cell carcinoma of the esophagus who were asked to participate in a phase III trial treatment either immediate surgery (n = 24) or plus preoperative chemotherapy 22), only 46 agreed randomization. A priori, 13 chose before and 18 only. The complete program consisted three cycles fluorouracil, 1 g/m2 per day for 5 days, cisplatin, 20 mg/m2 days. response rate was 50% (17 34 patients). Side effects therapy higher than expected based on results previous II studies. Two drug-related deaths observed. resectability group 79% (33 42 patients) compared 70% (19 27 receiving chemotherapy. postoperative rates septic complications (41% [11 patients] vs 26% patients]) respiratory disorders (48% [13 31% those treated Surgery-related mortality increased (19% [five (10% [four patients]). Patients responding had prolonged survival (median, months) nonresponders months), but median identical (10 months). We conclude that regime used this multi-institutional neither influences nor increases overall localized esophageal cancer. However, is associated considerable side high rate.